ACUR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACUR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Acura Pharmaceuticals's Enterprise Value is $0.30 Mil. Acura Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 was $-0.68 Mil. Therefore, Acura Pharmaceuticals's EV-to-EBIT for today is -0.44.
The historical rank and industry rank for Acura Pharmaceuticals's EV-to-EBIT or its related term are showing as below:
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Acura Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2021 was $32.68 Mil. Acura Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 was $-0.68 Mil. Acura Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was -2.08%.
The historical data trend for Acura Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Acura Pharmaceuticals's EV-to-EBIT falls into.
Acura Pharmaceuticals's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 0.300 | / | -0.679 | |
= | -0.44 |
Acura Pharmaceuticals's current Enterprise Value is $0.30 Mil.
Acura Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acura Pharmaceuticals (OTCPK:ACUR) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Acura Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Dec. 2021 ) | = | EBIT | / | Enterprise Value (Q: Dec. 2021 ) |
= | -0.679 | / | 32.6815 | |
= | -2.08 % |
Acura Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2021 was $32.68 Mil.
Acura Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Acura Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Bruce F Wesson | director | 1827 PACIFIC ST BROOKLYN NY 11233 |
William G Skelly | director | C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067 |
George K Ross | director | 1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596 |
James F Emigh | officer: VP, Corporate Development | |
Immanuel Thangaraj | director | 10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380 |
Robert A Seiser | officer: VP, Treasurer & Controller | C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067 |
Robert B Jones | officer: President & CEO | C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067 |
Albert W Brzeczko | officer: VP Pharmaceutical Sciences APT | C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067 |
Peter A Clemens | officer: Senior VP & CFO | C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233 |
Abuse Deterrent Pharma, Llc | 10 percent owner | 333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202 |
Claudius Llc | 10 percent owner | C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020 |
John Schutte | 10 percent owner | 9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233 |
Galen Partners Iii L P | 10 percent owner | 610 FIFTH AVE 5TH FL NEW YORK NY 10020 |
Galen Management, Llc | 10 percent owner | 680 WASHINGTON BLVD, STAMFORD CT 06901 |
Galen Employee Fund Iii Lp | 10 percent owner | 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020 |
From GuruFocus
By Marketwired 07-03-2019
By Marketwired 03-31-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.